Trial Profile
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Intravenous Delivery of Allogeneic Cardiosphere-Derived Cells in Subjects With Duchenne Muscular Dystrophy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs CAP-1002 (Primary)
- Indications Duchenne muscular dystrophy
- Focus Registrational; Therapeutic Use
- Acronyms HOPE-2
- Sponsors Capricor Therapeutics
- 06 Mar 2024 According to a Capricor Therapeutics media release, as the patients enter their fourth year of CAP-1002 continuous treatment, the company plan to discuss options for potential expedited approval pathways with the FDA and in connection with these efforts, look forward to sharing the three-year results in the second quarter of this year.
- 06 Mar 2024 According to a Capricor Therapeutics media release, the Company will present the positive 24-month results from its HOPE-2 open-label extension (OLE) study with lead asset, CAP-1002, for the treatment of Duchenne muscular dystrophy (DMD) at this years MDA Clinical and Scientific Conference.
- 29 Feb 2024 According to a Capricor Therapeutics media release, the company plan to report 3-year data from HOPE-2 open-label extension (OLE) Trial in Q2 2024.